Journal Home
Search for

Volume 584, Issue 4, Pages 701-706 (19 February 2010)


View previous. 11 of 34 View next.

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities

Edited by Robert Barouki

Majambu MbikayabcCorresponding Author Informationemail address, Francine Siroisa, Janice Maynea, Gen-Sheng Wanga, Andrew Chena, Thilina Dewpuraa, Annik Pratd, Nabil G. Seidahd, Michel Chretienabc, Fraser W. Scottabc

Received 19 October 2009; received in revised form 7 December 2009; accepted 11 December 2009. published online 17 December 2009.

Abstract 

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver-secreted plasma enzyme, restricts hepatic uptake of low-density lipoprotein (LDL) cholesterol by promoting the degradation of LDL receptors (LDLR). PCSK9 and LDLR are also expressed in insulin-producing pancreatic islet β cells, possibly affecting the function of these cells. Here we show that, compared to control mice, PCSK9-null male mice over 4months of age carried more LDLR and less insulin in their pancreas; they were hypoinsulinemic, hyperglycemic and glucose-intolerant; their islets exhibited signs of malformation, apoptosis and inflammation. Collectively, these observations suggest that PCSK9 may be necessary for the normal function of pancreatic islets.

a Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

b Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

c Division of Endocrinology and Metabolism, The Ottawa Hospital, Ottawa, Ontario, Canada

d Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada

Corresponding Author InformationCorresponding author. Present address: Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada K1Y 4E9. Fax: +1 613 761 4355.

PII: S0014-5793(09)01064-3

doi:10.1016/j.febslet.2009.12.018


View previous. 11 of 34 View next.